A Single Dose, Fasting state, Crossover Replicate Bioequivalence Study of Naproxen 500 mg/Esomeprazole 20 mg, modified-release tablets (Antibiotice S.A.) vs. Vimovo® 500 mg/20 mg film-coated tablets (Grunenthal Gmbh)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515662-14-00

Acronym

NAESAIS 02/2024

Enrollment

Registered

2024-10-31

Start date

2024-10-31

Completion date

2024-12-18

Last updated

2024-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026